Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Fineline Cube Apr 27, 2026
Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Fineline Cube Apr 27, 2026
Policy / Regulatory

Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers

Fineline Cube Apr 11, 2023

The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial

Fineline Cube Apr 11, 2023

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...

Company Drug

JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial

Fineline Cube Apr 11, 2023

China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...

Company Deals Digital

Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China

Fineline Cube Apr 11, 2023

China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...

Company

CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China

Fineline Cube Apr 11, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...

Company Deals

Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs

Fineline Cube Apr 11, 2023

China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed...

Hospital Policy / Regulatory

NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021

Fineline Cube Apr 11, 2023

The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis...

Company Deals

Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation

Fineline Cube Apr 11, 2023

Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan...

Medical Device Policy / Regulatory

Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables

Fineline Cube Apr 11, 2023

The Hebei medical drug and device centralized procurement center has announced the start of the...

Company Drug

Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments

Fineline Cube Apr 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...

Company Deals

Arctic Vision Partners with Sinopharm Group for Ophthalmic Product Distribution in China

Fineline Cube Apr 11, 2023

China-based ophthalmology specialist Arctic Vision has entered into a strategic partnership with Sinopharm Group Distribution...

Drug Policy / Regulatory

FDA Issues Complete Response Letters to Six Novel Drugs in Q1 2023

Fineline Cube Apr 10, 2023

According to an analysis, the US FDA issued complete response letters (CRLs) to six novel...

Company Deals

Bioyond Robotics Secures $29 Million in Series A and A+ Financing Rounds

Fineline Cube Apr 10, 2023

Bioyond Robotics, a Shanghai-based intelligent automation company, has reportedly raised around RMB 200 million (USD...

Policy / Regulatory

Henan Province Sees 53.6% Price Reduction in Neuro and Peripheral Intervention Consumables Tender

Fineline Cube Apr 10, 2023

The Henan Province Public Resources Trading Center has released a notification regarding the completion of...

Company Deals

Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D

Fineline Cube Apr 10, 2023

China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...

Company

Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai

Fineline Cube Apr 10, 2023

Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a...

Company Drug

Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML

Fineline Cube Apr 10, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...

Company Medical Device

Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Apr 10, 2023

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company,...

Company Drug

MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment

Fineline Cube Apr 10, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...

Company Deals

AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research

Fineline Cube Apr 10, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute...

Posts pagination

1 … 530 531 532 … 657

Recent updates

  • Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B
  • CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers
  • Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant
  • Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang
  • Novartis Secures WHO Pre-Qualification for Coartem Baby, First Antimalarial Specifically Designed for Newborns and Infants Under 5 kg
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Brii Biosciences Presents Promising HBsAg Rebound Data for Elebsiran-Based Regimens at APASL 2026, Highlighting Potential Functional Cure Profile in Chronic Hepatitis B

Company Drug

CSPC Pharmaceutical Receives FDA Clearance to Launch First-in-Class KAT6 Inhibitor SYH2095 Clinical Trial for Advanced Cancers

Company Drug

Bristol-Myers Squibb and Pfizer Partner with Mark Cuban’s Cost Plus Drugs to Offer Eliquis at $345 for 30-Day Supply, Expanding Access to Blockbuster Anticoagulant

Company Drug

Henlius Biotech Launches Phase II/III Trial in Australia for Triple Combination Therapy in Squamous NSCLC Featuring Novel Anti-EGFR Antibody Pimurutamab and Approved PD-1 Inhibitor HanSiZhuang

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.